Overview
myDNA provides direct-to-consumer DNA testing and analysis to support precision health. Its pharmacogenomics service analyzes how a person’s genes influence their response to medications to help clinicians optimize drug choice and dosing, reducing adverse effects. It also offers nutrigenomics insights to tailor nutrition, fitness, sleep, and vitamin plans, with reports sent to the patient’s healthcare provider. The company operates online test kits and pharmacy partnerships and expanded globally through a merger with Gene by Gene/FamilyTreeDNA, now owned by the DBG Group; its goal is to use genetic information to improve treatment effectiveness and overall wellbeing.
Work here?Claim your company
Simplify's Take
What believers are saying
- Bupa started offering myDNA pharmacogenomic kits in Australia during 2025-2026.
- The Phoenix Trial positions myDNA for clinical adoption evidence across 2026.
- FamilyTreeDNA’s millions of users create low-cost cross-sell and sequencing upgrade demand.
What critics are saying
- Saathoff v. Gene by Gene continued in arbitration after May 19, 2026.
- Illinois genetic-privacy claims over tracking pixels threaten FamilyTreeDNA’s trust and margins.
- DBG Health can starve myDNA of capital if pharmacy priorities shift in 2026.
What makes myDNA unique
- DBG Health owns myDNA, Gene by Gene, and FamilyTreeDNA across health and ancestry.
- FamilyTreeDNA partnered with Twist Bioscience in February 2026 for high-coverage sequencing.
- myDNA’s PGx platform targets prescribed medications through clinician-delivered genetic reports.
Help us improve and share your feedback! Did you find this helpful?